Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Canada: Supreme Court issues decision in Merck Frosst v Canada (Health) concerning Access to Information request regarding new drug submission by competitor (Excess Copyright)

Escitalopram – Netherlands: District Court of The Hague finds escitalopram patent partially valid: Lundbeck v Tiefenbacher (EPLAW)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Another Indian generics company, Emcure, signs with patent pool (IP Watch)

Could co-operation help pull pharma back from the cliff edge? (IAM)

WHO group to consult on pandemic flu framework in lead-up to assembly (IP Watch)

Is the polio vaccine an anti-patent success story? (BIOtechNOW)

Canada: Supreme Court issues decision in Merck Frosst v Canada (Health) concerning Access to Information request regarding new drug submission by competitor (Excess Copyright)

Canadian pharma: High prices, low research & development (Michael Geist)

Macau: Patent term extension in Macau (The SPC Blog) (The SPC Blog)

US: A solution in search of a problem: Safety of Untested and New Devices Act of 2012 (FDA Law Blog)

US: GAO report criticizes FDA on antibiotic labeling; finds no evidence of encouraged innovation (FDA Law Blog)

US: Senators Casey and McCain introduce bill to streamline de novo process and reclassify preamendment devices (FDA Law Blog)

US: CAFC interprets 35 USC 135(b) in Adair v Carter (IPBiz) (Patent Docs)

US: District Court finds that deadline to file PTA action was tolled by request for reconsideration: Bristol Meyers Squibb v Kappos (Pharma Patents)

US: How to best protect patents on new synthetic processes and intermediates in United States: Understanding “material change” exception (IIPRD)

US: Enzo files patent infringement suits against Gen-Probe, Life Technology and Roche Molecular Systems based on defendants’ nucleic acid probe products (Patent Docs)

US: Exelixis files for PTA calculation review for patent entitled ‘Phosphatidylinositol 3-kinase Inhibitors and Methods of Their Use’ (Patent Docs)

 

Products

Advocin (Fluoroquinolone) – US: Bayer Healthcare files patent infringement suit against Pfizer based on planned launch of Advocin (Patent Docs)

Atorvastatin – EU: What is obvious – the route or the destination? T-777/08 Atorvastatin Polymorphs (IPKat)

Carac (Fluorouracil) – US: Valeant International files patent infringement complaint against Spear Pharmaceuticals in response to Para IV certification (Patent Docs)

Dexilant (Dexalansoprazole) – US: Takeda files patent infringement suit against Sandoz following Para IV challenge (Patent Docs)

Escitalopram – Netherlands: District Court of The Hague finds escitalopram patent partially valid: Lundbeck v Tiefenbacher (EPLAW)

Fortamet (Metformin) – US: CAFC stays relief pending appeal: Sciele Pharma v Lupin (Patently-O)

Gemzar (Gemcitabine) – France: Inventive step of a glycosylation process (Kluwer Patent Blog)

Lovenox (Enoxaparin) – US: DC District Court grants FDA summary judgment in generic Lovenox dispute: Sanofi-Aventis v FDA (FDA Law Blog)

Lumigan (Bimatoprost) – US: Allergan files patent infringement suit against Hi-Tech following Para IV challenge (Patent Docs)

Nexium (Esomeprazole) – US: Astrazeneca files patent infringement complaint against Torrent Pharmaceuticals following Para IV certification (Patent Docs)

Simcor (Niacin / Simvastatin) – US: Abbott Laboratories files patent infringement suit against Sandoz in reponse to Para IV certification filing (Patent Docs)